Published in Science on May 27, 2005
The selectivity of protein kinase inhibitors: a further update. Biochem J (2007) 15.73
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A (2010) 8.05
High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat Methods (2011) 5.68
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev (2011) 5.02
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem (2007) 4.45
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J (2006) 3.57
BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J (2007) 3.11
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell (2007) 2.56
A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nat Chem Biol (2007) 2.41
Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat Struct Mol Biol (2010) 2.34
Disparate proteome reactivity profiles of carbon electrophiles. Nat Chem Biol (2008) 2.25
The systematic functional analysis of Plasmodium protein kinases identifies essential regulators of mosquito transmission. Cell Host Microbe (2010) 2.13
RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol Cell (2009) 2.11
Targeting Mnks for cancer therapy. Oncotarget (2012) 1.96
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J (2008) 1.96
Target validation using chemical probes. Nat Chem Biol (2013) 1.83
Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett (2010) 1.82
Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol (2013) 1.81
betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell (2009) 1.77
Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc Natl Acad Sci U S A (2006) 1.73
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. Nat Chem Biol (2012) 1.67
Covalent docking of large libraries for the discovery of chemical probes. Nat Chem Biol (2014) 1.66
The chemical biology of protein phosphorylation. Annu Rev Biochem (2009) 1.59
Discovery of potent and selective covalent inhibitors of JNK. Chem Biol (2012) 1.55
DREADDs for Neuroscientists. Neuron (2016) 1.52
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest (2010) 1.50
Advances in fluorescence labeling strategies for dynamic cellular imaging. Nat Chem Biol (2014) 1.47
A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol (2010) 1.46
Ligand-directed tosyl chemistry for protein labeling in vivo. Nat Chem Biol (2009) 1.43
A coupled chemical-genetic and bioinformatic approach to Polo-like kinase pathway exploration. Chem Biol (2007) 1.42
Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One (2009) 1.37
Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res (2007) 1.33
How chemoproteomics can enable drug discovery and development. Chem Biol (2012) 1.27
Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med Chem (2010) 1.27
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nat Chem Biol (2014) 1.26
Activation of p90 ribosomal S6 kinase by ORF45 of Kaposi's sarcoma-associated herpesvirus and its role in viral lytic replication. J Virol (2007) 1.26
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene (2013) 1.23
Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. J Med Chem (2009) 1.23
Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J Am Chem Soc (2008) 1.21
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med (2010) 1.19
Adding an unnatural covalent bond to proteins through proximity-enhanced bioreactivity. Nat Methods (2013) 1.17
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett (2008) 1.17
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. Bioorg Med Chem Lett (2012) 1.12
Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. J Am Chem Soc (2011) 1.11
Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor. Biochemistry (2009) 1.10
ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1. J Biol Chem (2010) 1.07
RSK-mediated phosphorylation in the C/EBP{beta} leucine zipper regulates DNA binding, dimerization, and growth arrest activity. Mol Cell Biol (2010) 1.06
Mutations of glucocorticoid receptor differentially affect AF2 domain activity in a steroid-selective manner to alter the potency and efficacy of gene induction and repression. Biochemistry (2008) 1.02
Reactive oxygen species-induced activation of p90 ribosomal S6 kinase prolongs cardiac repolarization through inhibiting outward K+ channel activity. Circ Res (2008) 1.02
On the supertertiary structure of proteins. Nat Chem Biol (2012) 1.01
Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proc Natl Acad Sci U S A (2011) 1.01
RSK isoforms in cancer cell invasion and metastasis. Cancer Res (2013) 1.00
Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups. J Comput Aided Mol Des (2007) 0.99
BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol Cancer Res (2014) 0.99
p90RSK targets the ERK5-CHIP ubiquitin E3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunction. Circ Res (2012) 0.98
Rapamycin induces transactivation of the EGFR and increases cell survival. Oncogene (2009) 0.97
Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. J Biol Chem (2011) 0.97
Electrophilic affibodies forming covalent bonds to protein targets. J Biol Chem (2009) 0.96
Irreversible Nek2 kinase inhibitors with cellular activity. J Med Chem (2011) 0.96
Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interaction. Protein Sci (2012) 0.94
Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529. J Biol Chem (2007) 0.94
The PKARIalpha subunit of protein kinase A modulates the activation of p90RSK1 and its function. J Biol Chem (2009) 0.94
Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis (2013) 0.93
Ribosomal S6 kinase 2 directly phosphorylates the 5-hydroxytryptamine 2A (5-HT2A) serotonin receptor, thereby modulating 5-HT2A signaling. J Biol Chem (2008) 0.92
The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis. J Biol Chem (2013) 0.91
Selective kinase inhibition by exploiting differential pathway sensitivity. Chem Biol (2006) 0.91
Collective and individual migration following the epithelial-mesenchymal transition. Nat Mater (2014) 0.90
The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1. Cell Death Dis (2013) 0.89
Kinome-wide interaction modelling using alignment-based and alignment-independent approaches for kinase description and linear and non-linear data analysis techniques. BMC Bioinformatics (2010) 0.88
Programmed cell death in Leishmania: biochemical evidence and role in parasite infectivity. Front Cell Infect Microbiol (2012) 0.87
Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends Pharmacol Sci (2015) 0.87
Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. J Med Chem (2013) 0.86
p90 activation contributes to cerebral ischemic damage via phosphorylation of Na+/H+ exchanger isoform 1. J Neurochem (2010) 0.85
Recruitment and activation of RSK2 by HIV-1 Tat. PLoS One (2007) 0.85
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. Int J Cancer (2012) 0.85
A Rising Cancer Prevention Target of RSK2 in Human Skin Cancer. Front Oncol (2013) 0.85
RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. Mol Cancer Res (2014) 0.85
Incomplete protein packing as a selectivity filter in drug design. Structure (2005) 0.84
Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2. Biochemistry (2015) 0.84
Enabling and disabling polo-like kinase 1 inhibition through chemical genetics. ACS Chem Biol (2012) 0.84
p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia. Blood (2011) 0.83
Covalent stabilization of a small molecule-RNA complex. Bioorg Med Chem Lett (2011) 0.82
p90 RSK2 mediates antianoikis signals by both transcription-dependent and -independent mechanisms. Mol Cell Biol (2013) 0.82
The Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent manner. Biochem J (2015) 0.82
Excessive Na+/H+ exchange in disruption of dendritic Na+ and Ca2+ homeostasis and mitochondrial dysfunction following in vitro ischemia. J Biol Chem (2010) 0.82
Suppression of DNA-damage checkpoint signaling by Rsk-mediated phosphorylation of Mre11. Proc Natl Acad Sci U S A (2013) 0.81
p90 Ribosomal S6 kinase 2, a novel GPCR kinase, is required for growth factor-mediated attenuation of GPCR signaling. Biochemistry (2010) 0.81
The Role of Mitogen-Activated Protein Kinase-Activated Protein Kinases (MAPKAPKs) in Inflammation. Genes (Basel) (2013) 0.81
Cell biology. Lessons in rational drug design for protein kinases. Science (2005) 0.81
Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Invest New Drugs (2014) 0.80
Engineered Covalent Inactivation of TFIIH-Kinase Reveals an Elongation Checkpoint and Results in Widespread mRNA Stabilization. Mol Cell (2016) 0.80
Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. Bioorg Med Chem Lett (2015) 0.79
ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. Cell Death Dis (2012) 0.79
Role of p90(RSK) in regulating the Crabtree effect: implications for cancer. Biochem Soc Trans (2013) 0.79
Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. Org Biomol Chem (2012) 0.78
An SH2 domain model of STAT5 in complex with phospho-peptides define "STAT5 Binding Signatures". J Comput Aided Mol Des (2015) 0.78
The protein kinase complement of the human genome. Science (2002) 35.36
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature (1988) 7.82
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther (2000) 5.09
Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol (1999) 4.43
Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell (1997) 4.26
Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell (1999) 3.73
A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1. EMBO J (2000) 3.70
MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J (2003) 3.29
Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible by MAPK. J Biol Chem (1998) 3.29
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci U S A (1998) 3.18
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett (2001) 2.86
Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol (1999) 2.35
Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure (1999) 2.09
Identification of serine 380 as the major site of autophosphorylation of Xenopus pp90rsk. Biochem Biophys Res Commun (1997) 1.69
Coffin-Lowry syndrome: clinical and molecular features. J Med Genet (2002) 1.60
Characterization of the p90 ribosomal S6 kinase 2 carboxyl-terminal domain as a protein kinase. J Biol Chem (2002) 1.35
A kinase sequence database: sequence alignments and family assignment. Bioinformatics (2002) 1.33
600 ps molecular dynamics reveals stable substructures and flexible hinge points in cAMP dependent protein kinase. Biopolymers (1999) 1.32
Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II. Bioorg Med Chem Lett (2000) 1.11
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
IRE1 signaling affects cell fate during the unfolded protein response. Science (2007) 9.01
Targets of the cyclin-dependent kinase Cdk1. Nature (2003) 8.05
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A (2008) 5.97
High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat Methods (2011) 5.68
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91
A critical assessment of Mus musculus gene function prediction using integrated genomic evidence. Genome Biol (2008) 4.78
Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell (2009) 4.71
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem (2007) 4.45
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature (2013) 4.43
The site-specific installation of methyl-lysine analogs into recombinant histones. Cell (2007) 4.22
Features of selective kinase inhibitors. Chem Biol (2005) 4.07
Rewiring of genetic networks in response to DNA damage. Science (2010) 4.03
The unfolded protein response signals through high-order assembly of Ire1. Nature (2008) 3.87
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell (2010) 3.79
Targeting the cancer kinome through polypharmacology. Nat Rev Cancer (2010) 3.74
Bypassing a kinase activity with an ATP-competitive drug. Science (2003) 3.71
The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores. Nat Cell Biol (2005) 3.61
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J (2006) 3.57
Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal (2010) 3.35
A chemical-genetic strategy implicates myosin-1c in adaptation by hair cells. Cell (2002) 3.34
Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell (2006) 3.32
Substrate-specific translocational attenuation during ER stress defines a pre-emptive quality control pathway. Cell (2006) 3.26
Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science (2010) 3.20
Functional organization of the S. cerevisiae phosphorylation network. Cell (2009) 3.15
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Mechanism of actin network attachment to moving membranes: barbed end capture by N-WASP WH2 domains. Cell (2007) 3.04
Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell (2011) 2.99
A chemical-genetic approach to studying neurotrophin signaling. Neuron (2005) 2.93
Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science (2009) 2.82
A polybasic motif allows N-WASP to act as a sensor of PIP(2) density. Mol Cell (2005) 2.80
Control of landmark events in meiosis by the CDK Cdc28 and the meiosis-specific kinase Ime2. Genes Dev (2003) 2.79
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
The F box protein Dsg1/Mdm30 is a transcriptional coactivator that stimulates Gal4 turnover and cotranscriptional mRNA processing. Cell (2005) 2.75
Chemical genetic analysis of Apg1 reveals a non-kinase role in the induction of autophagy. Mol Biol Cell (2003) 2.72
Selective amygdalohippocampectomy versus anterior temporal lobectomy in the management of mesial temporal lobe epilepsy: a meta-analysis of comparative studies. J Neurosurg (2013) 2.71
Evolution of phosphoregulation: comparison of phosphorylation patterns across yeast species. PLoS Biol (2009) 2.67
Sequence-dependent sorting of recycling proteins by actin-stabilized endosomal microdomains. Cell (2010) 2.67
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res (2007) 2.62
Cdc42-dependent actin polymerization during compensatory endocytosis in Xenopus eggs. Nat Cell Biol (2003) 2.59
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell (2007) 2.56
Cotranslocational degradation protects the stressed endoplasmic reticulum from protein overload. Cell (2006) 2.54
Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates. Proc Natl Acad Sci U S A (2008) 2.53
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol (2005) 2.51
A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases. Nat Methods (2005) 2.47
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42
A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nat Chem Biol (2007) 2.41
A semisynthetic epitope for kinase substrates. Nat Methods (2007) 2.40
Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci U S A (2007) 2.37
Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. Sci Signal (2010) 2.36
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature (2012) 2.33
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell (2008) 2.32
JNK2 is a positive regulator of the cJun transcription factor. Mol Cell (2006) 2.32
Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol (2007) 2.31
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28
Two cyclin-dependent kinases promote RNA polymerase II transcription and formation of the scaffold complex. Mol Cell Biol (2004) 2.26
Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature (2010) 2.25
Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell (2007) 2.22
An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol (2008) 2.21
A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum. Nature (2005) 2.21
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res (2008) 2.20
The role of p58IPK in protecting the stressed endoplasmic reticulum. Mol Biol Cell (2007) 2.20
TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol Cell Biol (2009) 2.20
Nuclear HuR accumulation through phosphorylation by Cdk1. Genes Dev (2008) 2.14
Re-emerging superconductivity at 48 kelvin in iron chalcogenides. Nature (2012) 2.13
RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol Cell (2009) 2.11
An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol (2005) 2.11
To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front. J Cell Biol (2006) 2.10
Chemical genetics: where genetics and pharmacology meet. Cell (2007) 2.09
Arabidopsis MAP kinase 4 regulates salicylic acid- and jasmonic acid/ethylene-dependent responses via EDS1 and PAD4. Plant J (2006) 2.07
The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med (2015) 2.07
A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature (2011) 2.07